Comparison of RAMOSETRON (cas 132036-88-5) with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery
-
Add time:08/03/2019 Source:sciencedirect.com
BackgroundRAMOSETRON (cas 132036-88-5) is a new selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that reportedly has more potent antiemetic effects compared with other 5-HT3 receptor antagonists. The purpose of this study was to evaluate the efficacy of ramosetron for the prevention of postoperative nausea and vomiting (PONV) with that of ondansetron or placebo in high-risk patients undergoing gynaecological surgery.
We also recommend Trading Suppliers and Manufacturers of RAMOSETRON (cas 132036-88-5). Pls Click Website Link as below: cas 132036-88-5 suppliers
Prev:Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study
Next:Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) on duodenal acidification-induced gastric hypersensitivity in rats08/05/2019
- Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats08/04/2019
- Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study08/02/2019
- Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial08/01/2019
- RAMOSETRON (cas 132036-88-5) Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women07/31/2019
- RAMOSETRON (cas 132036-88-5) vs. RAMOSETRON (cas 132036-88-5) plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy: Prospective, randomized, and double-blind study07/30/2019
- Effect of RAMOSETRON (cas 132036-88-5) on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea07/29/2019
- Effects of prophylactic RAMOSETRON (cas 132036-88-5) and ondansetron on corrected QT interval during general anesthesia07/28/2019
- Comparison of RAMOSETRON (cas 132036-88-5) With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial07/27/2019
